ACT-CTU Clinical Trial Rounds - June 17, 2026

ACT-CTU Clinical Trial Rounds - June 17, 2026

by Dr. Marina Klein

Life & Natural Systems Medicine & Health MBGRMedical researchMBGR1Clinical trials
🎙 Dr. Marina Klein 👥 382 📅 June 18, 2026 ⏱ 59 min 👁 11 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

HIVclinical trialsnetworkpreventionCanada

Summary

Dr. Marina Klein presents the evolution and future directions of the CIHR Canadian HIV/AIDS & STBBI Clinical Trials Network (CTN+). She begins by acknowledging the network’s 30-year history, initially focused on HIV treatment and prevention, and its success in enrolling over 20,000 participants and training many researchers. The network has recently expanded its mandate to include other sexually transmitted and bloodborne infections (STBBI) and has adopted a more decentralized model with regional nodes. Key priorities include addressing the HIV epidemic in the prairies, particularly among Indigenous communities, and leveraging new prevention tools like injectable PrEP (cabotegravir and lenacapavir). The presentation highlights the network’s commitment to community engagement, including an Indigenous Guidance Circle and a Community Science Champions program. Dr. Klein also outlines the network’s funding structure, which supports infrastructure but not trials themselves, and describes the process for developing flagship studies through think tanks. She emphasizes the importance of collaboration and partnership in advancing clinical research.

156 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the strategic evolution of a major clinical trials network, offering a comprehensive overview of its structure, priorities, and challenges. The argumentation is solid, grounded in the presenter’s extensive experience and supported by specific examples, such as the REPRIEVE trial and the HIV PrEP-to-need ratio. The discussion of the prairies’ HIV crisis is compelling and well-supported by epidemiological data. The emphasis on community engagement and Indigenous partnerships reflects current best practices in research. However, the presentation is largely descriptive and lacks critical analysis of potential limitations or alternative approaches.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor through the use of specific data and references to well-known trials, such as REPRIEVE and the studies on injectable PrEP. However, no formal citations are provided, and the information is presented from the perspective of the network’s leadership, which may introduce bias. The title accurately reflects the content, which is a presentation on the network’s evolution and future plans. The video includes a brief question from the audience, but no detailed discussion of sources or methodology.

190 words

Title / Content Match

The title accurately reflects the content, which is a presentation on the evolution and expansion of a clinical trials network.

Quality & Reliability

8/10

Presentation by a recognized expert with extensive experience in HIV clinical trials, supported by specific data and references to ongoing studies. The content is largely based on the presenter's expertise and institutional knowledge, with some references to published trials (e.g., REPRIEVE) and current epidemiological data. No formal citations are provided in the video, but the information is consistent with established scientific knowledge.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • REPRIEVE trial — Mentioned as a practice-changing trial on statins for cardiovascular disease prevention in people living with HIV.
  • CIHR Canadian HIV/AIDS & STBBI Clinical Trials Network (CTN+) — The network being presented, with its history and evolution.

Concurring Sources

  • REPRIEVE trial — The presenter cites this trial as evidence of the network's involvement in practice-changing research.

Contribution & Novelties

The presentation offers an insider’s perspective on the strategic reimagining of a national clinical trials network, highlighting the shift towards regionalization, community engagement, and expansion beyond HIV. It provides a detailed account of the network’s structure, funding mechanisms, and priority-setting processes, which is valuable for researchers and policymakers. The discussion of the HIV crisis in the prairies and the potential of new injectable PrEP agents is particularly timely.

Pour aller plus loin :

  • HIV Prevention — Overview of HIV prevention methods, including PrEP.
  • Cabotegravir for PrEP — FDA approval of injectable cabotegravir for PrEP.
  • Lenacapavir — Information on lenacapavir as a long-acting PrEP option.

104 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a moderate technical level. This indicates a presentation that is rich in content and well-supported, but not overly technical, making it accessible to a broader audience.

Reliability 8/10